Cortexyme announces clinical hold on atuzaginstat’s Investigational New Drug Application for Alzheimer's disease.
Cortexyme is immediately implementing a cost reduction program to rationalize operations and to allow continued support for planned clinical milestones, providing an expected cash runway through 2024. The company intends to prioritize development of its next generation gingipain inhibitor, COR 588, in Alzheimer’s disease. COR 588 is currently completing a Phase 1 SAD/MAD study and results are expected in the second quarter 2022. In addition, Cortexyme plans to explore strategic alternatives for its coronavirus program and non-Alzheimer’s indications for COR 388. Cortexyme intends to provide a more detailed update on its pipeline and anticipated milestones for 2022 in the near future.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.